News Releases

Date	Title and Summary	View
Oct 19, 2020	JANSSEN DEMONSTRATES STRONG COMMITMENT TO RESEARCH AND DEVELOPMENT OF THERAPIES FOR INFLAMMATORY BOWEL DISEASES WITH NINE DATA PRESENTATIONS AT ACG 2020
Oct 16, 2020	Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV
Oct 16, 2020	Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA®▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU)
Oct 15, 2020	New First-in-Class Phase 3 Data Demonstrate TREMFYA® (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis
Oct 15, 2020	Johnson & Johnson to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
Oct 13, 2020	Johnson & Johnson Reports 2020 Third-Quarter Results - Sales of $21.1 billion reflecting an overall and operational increase of 1.7%, and adjusted operational increase of 2.0% despite the estimated negative impact of the COVID-19 pandemic - EPS of $1.33 increased 101.5%; adjusted EPS of $2.20 increased 3.8%* - Company increasing guidance for
Oct 12, 2020	STELARA® (ustekinumab) Five-Year Results Presented from Long-term Extension Study of Clinical Response and Remission in Patients with Moderate to Severe Crohn’s Disease
Oct 12, 2020	TREMFYA® (guselkumab) Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn’s Disease based on Interim Results from Phase 2 Study
Oct 08, 2020	Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate Agreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses NEW BRUNSWICK, N.J., Oct. 8, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on
Oct 06, 2020	Biosense Webster Receives FDA Approval for THERMOCOOL SMARTTOUCH® SF Ablation Catheter for the Treatment of Persistent Atrial Fibrillation